Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.73 USD

51.73
1,388,647

+0.47 (0.92%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Glaxo Signs Another Deal to Develop a Coronavirus Vaccine

by Zacks Equity Research

Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.

Regeneron Initiates Studies on Experimental Coronavirus Drug

by Zacks Equity Research

Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

Moderna Shares Lose Momentum After Meteoric Rise: Here's Why

by Zacks Equity Research

The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.

Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study

by Zacks Equity Research

Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus

by Kinjel Shah

Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.

Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug

by Zacks Equity Research

Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.

Sanofi (SNY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Sanofi (SNY) closed at $51.08 in the latest trading session, marking a +0.33% move from the prior day.

Ritujay Ghosh headshot

3 Stocks to Buy as Companies Speed Up Vaccine Production

by Ritujay Ghosh

Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.

Sanofi (SNY) is a Top Dividend Stock Right Now: Should You Buy?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.

Translate Bio Up on Vaccine Agreement Expansion With Sanofi

by Zacks Equity Research

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.

Company News for Jun 24, 2020

by Zacks Equity Research

Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.

Urmimala Biswas headshot

3 Best GARP Stocks to Beat Pandemic-Led Market Inefficiency

by Urmimala Biswas

The unprecedented global health crisis is providing a psychological shock to the investment world.

Sanofi Expands Agreement With Translate Bio for mRNA Vaccines

by Zacks Equity Research

Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. The companies are already developing a mRNA vaccine candidate to combat COVID-19.

Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine

by Zacks Equity Research

Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.

Regeneron Gets FDA Nod for Dupixent 300 Mg Pre-Filled Pen

by Zacks Equity Research

Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.

Novo Nordisk Completes Two Studies on Obesity Candidate

by Zacks Equity Research

Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.

Mylan Gets Favorable Ruling Against Biogen's Tecfidera Patent

by Zacks Equity Research

Mylan (MYL) wins the district court's decision against Biogen's lead MS drug's patent.

Sanofi (SNY) to Create Dedicated Vaccine Center in France

by Zacks Equity Research

Sanofi (SNY) plans to invest almost $690 billion to develop a new production site and research center in France with both dedicated to vaccines.

Kinjel Shah headshot

FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus

by Kinjel Shah

The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.

Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Sanofi (SNY) closed at $50.59, marking a +1.28% move from the previous day.

Mylan & Biocon's Semglee Wins FDA Approval for Diabetes

by Zacks Equity Research

Mylan (MYL) and partner Biocon gains FDA approval for diabetes treatment, Semglee.

Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash

by Zacks Equity Research

Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.

Pfizer's Eczema Candidate Meets All Goals in Study on Teens

by Zacks Equity Research

Pfizer's (PFE) investigational eczema treatment, abrocitinib, succeeds in a late-stage study under the JADE program in patients aged 12 years and above.

RedHill Files CTA for Coronavirus Study on Opaganib in Russia

by Zacks Equity Research

RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.

Lilly Begins Cardiovascular Outcomes Study on Tirzepatide

by Zacks Equity Research

Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.